Search Results - "WOLF, Jürgen"

An integral method for solving nonlinear eigenvalue problems by Beyn, Wolf-Jürgen

“…We propose a numerical method for computing all eigenvalues (and the corresponding eigenvectors) of a nonlinear holomorphic eigenvalue problem that lie within…”
Get full text

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial by Subbiah, Vivek, Wolf, Jürgen, Konda, Bhavana, Kang, Hyunseok, Spira, Alexander, Weiss, Jared, Takeda, Masayuki, Ohe, Yuichiro, Khan, Saad, Ohashi, Kadoaki, Soldatenkova, Victoria, Szymczak, Sylwia, Sullivan, Loretta, Wright, Jennifer, Drilon, Alexander

“…Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS activity that has shown efficacy in RET fusion-positive lung and thyroid…”
Get full text

Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC by Saleh, Mohamed Mahde, Scheffler, Matthias, Merkelbach-Bruse, Sabine, Scheel, Andreas Hans, Ulmer, Bastian, Wolf, Jürgen, Buettner, Reinhard

“…TP53 and KEAP1 are frequently mutated in NSCLC, but their prognostic value is ambiguous, particularly in localized stage tumors. This retrospective cohort…”
Get more information

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study by Morgensztern, Daniel, Besse, Benjamin, Greillier, Laurent, Santana-Davila, Rafael, Ready, Neal, Hann, Christine L, Glisson, Bonnie S, Farago, Anna F, Dowlati, Afshin, Rudin, Charles M, Le Moulec, Sylvestre, Lally, Satwant, Yalamanchili, Sreeni, Wolf, Jürgen, Govindan, Ramaswamy, Carbone, David P

“…Although extensive-stage small-cell lung cancer (SCLC) is highly responsive to first-line therapy, virtually all patients develop resistance with short…”
Get full text

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Focus on Pyrimidines, Pyridines and Pyrroles by Di Gion, Paola, Kanefendt, Friederike, Lindauer, Andreas, Scheffler, Matthias, Doroshyenko, Oxana, Fuhr, Uwe, Wolf, Jürgen, Jaehde, Ulrich

“…Pyrimidine (imatinib, dasatinib, nilotinib and pazopanib), pyridine (sorafenib) and pyrrole (sunitinib) tyrosine kinase inhibitors (TKIs) are multi-targeted…”
Get full text

On the smoothness of principal angles between subspaces and their application to angular values of dynamical systems by Beyn, Wolf-Jürgen, Hüls, Thorsten

“…In this work we provide detailed estimates of maximal principal angles between subspaces and we analyse their smoothness for smoothly varying subspaces. This…”
Get full text

On a generalized notion of metrics by Beyn, Wolf-Jürgen

“…In these notes we generalize the notion of a (pseudo) metric measuring the distance of two points, to a (pseudo) n -metric which assigns a value to a tuple of…”
Get full text

Stochastic C-Stability and B-Consistency of Explicit and Implicit Euler-Type Schemes by Beyn, Wolf-Jürgen, Isaak, Elena, Kruse, Raphael

“…This paper is concerned with the numerical approximation of stochastic ordinary differential equations, which satisfy a global monotonicity condition. This…”
Get full text

Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment by Buettner, Reinhard, Wolf, Jürgen, Thomas, Roman K

“…The advent of novel therapeutics that specifically target signaling pathways activated by genetic alterations has revolutionized the way patients with lung…”
Get full text

Stochastic C-Stability and B-Consistency of Explicit and Implicit Milstein-Type Schemes by Beyn, Wolf-Jürgen, Isaak, Elena, Kruse, Raphael

“…This paper focuses on two variants of the Milstein scheme, namely the split-step backward Milstein method and a newly proposed projected Milstein scheme,…”
Get full text

Spectral analysis of localized rotating waves in parabolic systems by Beyn, Wolf-Jürgen, Otten, Denny

“…In this paper, we study the spectra and Fredholm properties of Ornstein-Uhlenbeck operators where is the profile of a rotating wave satisfying as , the map is…”
Get full text

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas by Scheel, Andreas H, Dietel, Manfred, Heukamp, Lukas C, Jöhrens, Korinna, Kirchner, Thomas, Reu, Simone, Rüschoff, Josef, Schildhaus, Hans-Ulrich, Schirmacher, Peter, Tiemann, Markus, Warth, Arne, Weichert, Wilko, Fischer, Rieke N, Wolf, Jürgen, Buettner, Reinhard

“…Immunohistochemistry of the PD-L1 protein may be predictive for anti-PD-1 and anti-PD-L1 immunotherapy in pulmonary adenocarcinoma and in clinically unselected…”
Get full text

Reply to: "Survival Analysis of TP53 Co-Mutations Should be Interpreted More Cautiously" by Saleh, Mohamed Mahde, Scheffler, Matthias, Merkelbach-Bruse, Sabine, Wolf, Jürgen, Buettner, Reinhard

Get more information

Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial by Kim, Dong-Wan, MD, Mehra, Ranee, MD, Tan, Daniel S W, MD, Felip, Enriqueta, MD, Chow, Laura Q M, MD, Camidge, D Ross, Prof, Vansteenkiste, Johan, Prof, Sharma, Sunil, Prof, De Pas, Tommaso, MD, Riely, Gregory J, MD, Solomon, Benjamin J, MBBS, Wolf, Jürgen, Prof, Thomas, Michael, Prof, Schuler, Martin, Prof, Liu, Geoffrey, MD, Santoro, Armando, Prof, Sutradhar, Santosh, PhD, Li, Siyu, PhD, Szczudlo, Tomasz, MD, Yovine, Alejandro, MD, Shaw, Alice T, Dr

“…Summary Background ALK -rearranged non-small-cell lung cancer (NSCLC) is sensitive to ALK tyrosine kinase inhibitors (ALK inhibitors) such as crizotinib, but…”
Get full text

Moving the goalposts while scoring―the dilemma posed by new PET technologies by Rogasch, Julian M.M., Boellaard, Ronald, Pike, Lucy, Borchmann, Peter, Johnson, Peter, Wolf, Jürgen, Barrington, Sally F., Kobe, Carsten

Get full text

Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR -Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance by Schuler, Martin, Hense, Jörg, Darwiche, Kaid, Michels, Sebastian, Hautzel, Hubertus, Kobe, Carsten, Lueong, Smiths, Metzenmacher, Martin, Herold, Thomas, Zaun, Gregor, Laue, Katharina, Drzezga, Alexander, Theegarten, Dirk, Nensa, Felix, Wolf, Jürgen, Herrmann, Ken, Wiesweg, Marcel

“…Targeted therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has established the precision oncology paradigm in lung cancer…”
Get full text

Do core-selecting Combinatorial Clock Auctions always lead to high efficiency? An experimental analysis of spectrum auction designs by Bichler, Martin, Shabalin, Pasha, Wolf, Jürgen

“…For many years the Simultaneous Multi-Round Auction (SMRA) has been the primary auction design for spectrum sales worldwide. Recently, the core-selecting…”
Get full text

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Focus on 4-Anilinoquinazolines by Scheffler, Matthias, Di Gion, Paola, Doroshyenko, Oxana, Wolf, Jürgen, Fuhr, Uwe

“…The 4-anilinoquinazolines (gefitinib, erlotinib and lapatinib) are members of a class of potent and selective inhibitors of the human epidermal growth factor…”
Get full text

Stratified Treatment in Lung Cancer by Michels, Sebastian, Wolf, Jürgen

“…Even though great efforts have been made to improve chemotherapy-based treatment approaches for lung cancer, the prognosis of patients with advanced and…”
Get more information

MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung by Schildhaus, Hans-Ulrich, Schultheis, Anne M, Rüschoff, Josef, Binot, Elke, Merkelbach-Bruse, Sabine, Fassunke, Jana, Schulte, Wolfgang, Ko, Yon-Dschun, Schlesinger, Andreas, Bos, Marc, Gardizi, Masyar, Engel-Riedel, Walburga, Brockmann, Michael, Serke, Monika, Gerigk, Ulrich, Hekmat, Khosro, Frank, Konrad F, Reiser, Marcel, Schulz, Holger, Krüger, Stefan, Stoelben, Erich, Zander, Thomas, Wolf, Jürgen, Buettner, Reinhard

“…MET is a potential therapeutic target in lung cancer and both MET tyrosine kinase inhibitors and monoclonal antibodies have entered clinical trials. MET…”
Get full text